JITC丨Combination of Autologous Transplantation and CAR-T Cells Enhances Outcomes in Refractory Large B-Cell Lymphoma: Findings from the Team of Professor Dehui Zou and Professor WentingZheng

JITC丨Combination of Autologous Transplantation and CAR-T Cells Enhances Outcomes in Refractory Large B-Cell Lymphoma: Findings from the Team of Professor Dehui Zou and Professor WentingZheng

Chimeric antigen receptor T-cell (CAR-T) therapy is one of the most promising salvage treatments for relapsed/refractory large B-cell lymphoma (r/r LBCL), offering durable remission for about one-third of patients. However, the remaining two-thirds either fail to respond to CAR-T therapy or experience relapse, resulting in poor survival outcomes. This underscores the urgent need to explore methods to enhance the efficacy of CAR-T therapy.
2025 CASH丨Dr. Suning Chen: Focusing on Annual Advances in AML—Integrating Innovation for a Better Future

2025 CASH丨Dr. Suning Chen: Focusing on Annual Advances in AML—Integrating Innovation for a Better Future

The 5th Annual Meeting of Chinese Alliance for Societies of Hematology (2025 CASH) was held in Tianjin from January 3 to 5, featuring the theme of “Comprehensive Hematology, Comprehensive Health, and Comprehensive Well-being.” The event invited top hematology experts from China and abroad to discuss the latest advancements and future trends in the field.
2025 CASH丨Dr. Rong Fu: Interpretation of the PNH China Guidelines

2025 CASH丨Dr. Rong Fu: Interpretation of the PNH China Guidelines

The 5th Annual Meeting of Chinese Alliance for Societies of Hematology (2025 CASH) was held in Tianjin from January 3 to 5, under the theme “Comprehensive Hematology, Comprehensive Health, and Comprehensive Well-being.” Top hematology experts from China and abroad were invited to discuss the latest advancements and future trends in hematology.
2025 CASH丨Another Milestone! Dr. Jing Pan’s Team Recognized in the Top 10 Hematology Research Advancements of 2024

2025 CASH丨Another Milestone! Dr. Jing Pan’s Team Recognized in the Top 10 Hematology Research Advancements of 2024

From January 3–5, 2025, the 5th Annual Meeting of Chinese Alliance for Societies of Hematology (CASH) was held in Tianjin under the theme “Comprehensive Hematology, Comprehensive Health, and Comprehensive Well-being.” As a key highlight of the conference, the Top 10 Hematology Research Advancements of 2024 were announced during the closing ceremony, recognizing significant scientific achievements in the field of hematology over the past year.
Annual Review | Prof. Jun Ma: 2024 Updates on Guidelines and Advances in Acute Lymphoblastic Leukemia (ALL)

Annual Review | Prof. Jun Ma: 2024 Updates on Guidelines and Advances in Acute Lymphoblastic Leukemia (ALL)

In recent years, the field of hematologic oncology has witnessed remarkable breakthroughs, with acute lymphoblastic leukemia (ALL) emerging as a focal point of progress. Chinese researchers have made significant contributions, driving milestone advancements in both research and clinical practice. To usher in the new year, Hematology Frontier invited Professor Jun Ma from the Harbin Institute of Hematology and Oncology to provide an in-depth review of the key developments in ALL during 2024. This comprehensive analysis aims to guide clinical practice and inspire future research.